Brightmind.AI develops neurotechnology solutions for personalized brain stimulation, focusing on migraine prevention and other neurological challenges. Self-described as using cutting-edge research to improve brain health.

Brightmind.AI

QuantActions provides personalized health solutions powered by real-time data, offering integration for health metrics and trends.

QuantActions

Migränhjälpen provides specialist help for diagnosing and treating severe headaches and migraines, utilizing digital consultations without the need for physical examinations.

Migränhjälpen

Marigold Health Foods produces high-quality, natural, plant-based food products, including bouillon, gravy and stock cubes, snacks, and other items.  The self-described products use only natural ingredients and avoid artificial additives.

Marigold Health Foods

Brightmind.AI | 1,982 followers on LinkedIn. We develop cutting-edge personalised neuromodulation technologies to solve the greatest challenges to brain health. | We develop cutting-edge personalised neuromodulation technologies to solve the greatest challenges to brain health.

PhD Engineer

Dr. Rand K Almajidy

Versatile Engineer and Project Manager | sustainable family farming | outdoor enthusiast

Paul Batthyány

Neurotech x AI | Founder @Brightmind.AI - Revolutionising Migraine Treatment at Home | Forbes 30 under 30

Tamara Gerbert

PhD | Electronics Engineer

Diego Milardovich

🌟 Exciting News! Brightmind.ai is proud to be selected as one of three Austrian startups to reach the semi-finals of the prestigious EIT Health Catapult competition! 🌟 The EIT Health Catapult is one of Europe’s most competitive programs, supporting top healthcare innovators with funding, mentorship, and visibility. This recognition highlights Brightmind.ai ’s commitment to transforming migraine treatment with our innovative, non-invasive brain stimulation technology. Every year, migraines disrupt the lives of over 80 million people across the EU and the US, with significant impacts on careers, education, and well-being. At Brightmind.ai , we are developing a personalized, at-home solution that offers migraine sufferers a safer, more effective alternative to traditional therapies. This milestone with EIT Health is a significant step toward making our vision a reality. To accelerate our growth, we are currently fundraising and are open to discussions with angel investors, as well as pre-seed and seed investors who share our vision of a future free from migraine pain. Join us in bringing this breakthrough technology to those who need it most! Thank you to EIT Health for the opportunity, and congratulations to the other startups moving forward! We are thrilled to be on this journey with incredible innovators. Together, we’re shaping the future of healthcare. 👉 Link to article: https://lnkd.in/dHqeEWF8 #BrightmindAI #EITHealth #HealthcareInnovation #MigraineTreatment #BrainStimulation #StartupJourney #HealthTech #Fundraising Gregor Kowarik Uzair Rashid Tamara Gerbert Luca F. Ticini José Buela Dr. Rand K Almajidy Peter Hacker Ingrid Kelly Spillmann Markus Wanko

Rene Gilvert

It’s Migraine Awareness Day, let’s take a moment together to reflect on the burden and the solution we are working.

We are thrilled to announce that Shivang Joshi MD,MPH,RPh,FAHS has joined the Clinical Advisory Board of Brightmind.AI ! 🎉 Dr. Joshi brings a wealth of expertise driving research in the field of headache and migraine. Before becoming Director of Headache Medicine and Clinical Research at COMMUNITY NEUROSCIENCE SERVICES , Dr. Joshi completed his Neurology Residency at the Beth Israel Medical Center and was Instructor of Neuroscience at the Harvard Medical School . His research in headache medicine has been recognized with the “Frontiers in Headache Research” Scholarship Award from the American Headache Society . Dr. Joshi shares our excitement, stating: "I am excited about the potential of Brightmind.AI ’s technology to revolutionize the way we treat migraines and other neurological disorders. Among providers and clinical experts, neuromodulation for migraine experiences growing interest due to its outstanding safety profile while offering at least comparable or even superior clinical outcomes to traditional medications." At Brightmind.AI , our mission is to transform migraine and headache management through innovative, patient-centered solutions. Dr. Joshi’s established expertise in clinical excellence and his visionary approach will be crucial in guiding our clinical strategy, facilitating regulatory approvals, and introducing our pioneering treatments to the market. With Dr. Joshi on board, we are more confident than ever in bringing innovative, effective treatments to those suffering from neurological conditions. Please join us in welcoming Dr. Joshi to the Brightmind.AI family. We look forward to the incredible advancements we will achieve together!

We are excited to share that Peter McAllister, M.D., FAAN , a distinguished Neurologist and Migraine Expert, is joining Brightmind.AI 's Clinical Advisory Board! 🎉 Dr. McAllister’s extensive expertise in Neurology and Headache Medicine, coupled with his leadership roles as Medical Director of the New England Institute for Neurology and Headache and Chief Medical Officer of the New England Institute for Clinical Research and Ki Clinical Research , make him an invaluable addition to our team. His academic roles at Yale University School of Medicine and Quinnipiac University 's Frank H. Netter School of Medicine further underscore his commitment to advancing the field. At Brightmind.AI , we are dedicated to transforming migraine and headache management through innovative, patient-centered solutions. Dr. McAllister’s proven track record in clinical excellence and his forward-thinking approach will be instrumental in shaping our clinical strategy, supporting regulatory approvals, and bringing our groundbreaking treatments to market. Together, we are poised to make a significant impact in the lives of those affected by migraine and headache disorders. Dr. McAllister’s vision aligns perfectly with our mission to push the boundaries of what’s possible in healthcare. Please join us in welcoming Dr. McAllister to the Brightmind.AI family. We look forward to the incredible advancements we will achieve together! #BrightmindAI #ClinicalAdvisoryBoard #HealthcareInnovation #MigraineTreatment #Neurology

At Brightmind.AI , we're revolutionizing at-home healthcare by making advanced rTMS technology accessible right from your living room. Join Luca F. Ticini as he explores how our innovative at-home rTMS device will opening up new possibilities for migraine treatment and beyond, empowering patients to manage their health with ease and efficiency. Discover a new frontier in healthcare where convenience meets clinical excellence. Tamara Gerbert Rene Gilvert Uzair Rashid Theresa Winkler Dr. Rand K Almajidy José Buela Diego Milardovich Paul Batthyány Peter Hacker #HealthTech #AtHomeHealthcare #NeuroTech #Innovation #PatientCare #DigitalHealth #MedicalDevices #BrainHealth #Neuroscience #FutureOfHealthcare

Excited to share Luca F. Ticini article on migraine treatment advancements! Discover how neuromodulation technologies like at home magnetic neuromodulation is revolutionizing care for migraine sufferers. These non-invasive, drug-free methods offer new hope and improved quality of life. Dive into the future of migraine management and meet Dr. Luca Ticini, a pioneer in this field. #MigraineTreatment #Neuromodulation #MedicalInnovation #HealthcareTech #BrainHealth #ChronicPain #PatientCare #BrightmindAI Rene Gilvert Gregor Kowarik Tamara Gerbert José Buela Paul Batthyány Dr. Rand K Almajidy Theresa Winkler Uzair Rashid Diego Milardovich

Welcome to the team, Uzair! We're excited to announce that Uzair Rashid has joined Brightmind.AI as our Chief Commercial Officer. Uzair is a recognized expert in driving commercial growth and pioneering digital transformation in the healthcare sector. His outstanding contributions include the development of a commercial tech platform at Cardinal Health , establishing a data office and monetization strategy at Pure Health Group, and scaling innovative care delivery models at CVS Health and Blue Cross Blue Shield of Massachusetts . Uzair, an Executive Mentor & Industry Expert at Harvard Innovation Labs , holds a Master's degree in Data Science from Harvard University and has received executive training from Massachusetts Institute of Technology in Data Monetization Strategy. We are looking forward to Uzair's impact at Brightmind.AI , spearheading our commercial strategies, focusing on maximizing reimbursement and distribution channels in the US to ensure our innovative solutions reach those who need them most!

𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞 𝐢𝐧 𝐚𝐧 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐦𝐢𝐠𝐫𝐚𝐢𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐬𝐭𝐮𝐝𝐲 𝐚𝐭 𝐀𝐊𝐇 𝐕𝐢𝐞𝐧𝐧𝐚 We are thrilled to announce our upcoming #clinicaltrial under the expert guidance of Prof. Christian Wöber , 𝗛𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗛𝗲𝗮𝗱𝗮𝗰𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰 at Universitätsklinikum AKH Wien . This initiative is aimed at pioneering new pathways in non-invasive brain stimulation for preventing 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲 attacks, a literal pain point affecting one million people across Austria. Prof. Wöber's dedication to helping migraine patients has also motivated him to write his recent book, which assists patients in identifying their profiles for the right treatment. Learn more here: https://lnkd.in/d3MxinJP 𝗪𝗲 𝗡𝗲𝗲𝗱 𝗬𝗼𝘂𝗿 𝗛𝗲𝗹𝗽! Are you or someone you know 𝘀𝘁𝗿𝘂𝗴𝗴𝗹𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝘁 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲𝘀? If you experience more than 4 migraine attacks a month, you might be eligible to participate in our ongoing study. This is a unique opportunity to access innovative treatments and contribute to research that could change the lives of migraine sufferers worldwide. 𝗛𝗼𝘄 𝘁𝗼 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲: 𝗘𝗹𝗶𝗴𝗶𝗯𝗶𝗹𝗶𝘁𝘆: Individuals experiencing more than 𝟰 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲 𝗮𝘁𝘁𝗮𝗰𝗸𝘀 𝗽𝗲𝗿 𝗺𝗼𝗻𝘁𝗵 and able to travel to the AKH in 𝗩𝗶𝗲𝗻𝗻𝗮. 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: Access to cutting-edge treatments and the chance to contribute to groundbreaking research. 𝗛𝗼𝘄 𝘁𝗼 𝗔𝗽𝗽𝗹𝘆: Express your interest and provide your preferred start date here: https://lnkd.in/d2hZat5A . Join us in advancing migraine research and developing more effective treatments. Your participation in the Brightmind study could help bring relief to millions. #MigraineResearch #ClinicalTrials #AKHVienna #Migraine

It is a pleasure to announce our latestest brightmind addition: Dr. Rand K Almajidy who holds a PhD in Medical Engineering focusing on the design & validation of a dual modality brain computer interface. With more than 10 years of experience and publications in #neuroelectronic systems interfacing with various disciplines, she will be driving innovation at Brightmind.AI ! Welcome Rand!!

Metric
Company Name	Brightmind.AI	QuantActions	Migränhjälpen	Marigold Health Foods
Symbol
MSH ID	AI:BRIGHTMIND	COM:QUANTACTIONS	SE:MIGRANHJALPEN	UK:CO:MARIGOLDHEALTHFOODS
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Consumer Goods
Industry	Medical Devices	Health Technology	Health Care	Food and Beverage
Country	US	DE	SE	GB
Stage
Employee Count
Website	brightmind.ai	quantactions.com	migranhjalpen.se	marigoldhealthfoods.co.uk
LinkedIn	brightmind-ai	quantactions	migranhjalpen	marigold-health-foods-limited
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			509
Web Traffic Growth			4.63
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BRIG

AI:BRIGHTMIND

Brightmind.AI

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue